Volume 26, Number 8—August 2020
Research
Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France
Table 3
Patient age, y/sex, | Fundus examination | Visual color† | Visual field | Involvement | Other | Linezolid duration, mo | Months from start of linezolid to onset of optic neuropathy | Reversibility after linezolid withdrawal |
---|---|---|---|---|---|---|---|---|
37/M |
Papillary edema |
Tritanopia |
BSE |
B |
None |
3.4 |
0.0 |
No |
42/M |
WNL |
Tritanopia |
Aciform scotoma |
B |
None |
13.5 |
1.4 |
No |
20/M |
WNL |
Tritanopia |
WNL |
B |
None |
18.5 |
1.6 |
Yes |
40/M |
WNL |
Tritanopia |
BSE |
B |
Optic neuropathy confirmed by VEP |
15.3 |
14.6 |
Yes |
48/M |
WNL |
Tritan |
BSE |
B |
None |
5.7 |
9.3 |
No |
43/M |
WNL |
Tritanopia |
NA |
U |
None |
11.6 |
17.9 |
Yes |
40/M |
WNL |
Tritanopia |
BSE |
U |
None |
18 |
NA |
Yes |
39/M |
WNL |
Tritanopia |
BSE |
B |
None |
23.1 |
15.4 |
Yes |
42/M |
WNL |
Tritanopia |
BSE |
B |
None |
19.4 |
5.2 |
Yes |
40/M |
WNL |
Tritanopia |
NA |
B |
4.4 |
1.0 |
No |
|
34/M |
Papillary edema |
Tritanopia |
BSE |
B |
Optic neuropathy confirmed by VEP |
16.6 |
15.1 |
Yes |
21/M |
Papillary edema |
Tritanopia |
Scotoma |
B |
Optic neuropathy confirmed by VEP |
7.1 |
8.2 |
Yes |
23/F |
Hyperemia of optical nerve |
Tritanopia |
BSE |
B |
None |
NA |
10.2 |
Yes |
30/M | Hyperemia of optical nerve | Tritan | BSE | B | None | 19.1 | 16.2 | Yes |
*B, bilateral; BSE, blind spot enlargement; NA, not available; U, unilateral, VEP, visual evoked potential; WNL, within normal limits.
†Tritan, common blue–yellow color blindness.; tritarnopia, blue–yellow confusion typical in patients with optic neuropathies.
Page created: June 12, 2020
Page updated: July 17, 2020
Page reviewed: July 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.